A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: Safety and immunity

Influenza Vaccination in Autoimmune Rheumatic Disease Patients

“…Other papers reported a modest reduction or a similar humoral response in SLE patients, but compared to the healthy control group (Brodman et al 1978;Mercado et al 2004;Holvast et al 2006). In several controlled studies in SLE patients a similar humoral response was established after influenza immunization compared to the healthy control group and immunosuppressive therapy has no significant effect on the response to vaccination (Louie et al 1978;Lu et al 2011). On the other hand, there are reports indicating a decreased humoral response in SLE patients treated with immunosuppressive therapy (Abu-Shakra et al 2002;Wiesik-Szewczyk 2010).…”

Vaccination of patients with autoimmune inflammatory rheumatic diseases

“…Although several studies have found that autoantibody titres increase in some patients with an AIRD after influenza vaccination, 87,98,139,140 other studies could not confirm these findings, 141 and in the majority of cases this increase in autoantibody titre was not associated with clinical disease activity. 57,58 In most of the latest studies of the efficacy of influenza vaccination in patients with RA, safety is considered and yet no significant influence of vaccination on disease activity has been reported.…”

“…96 One study of patients with SLE did not find significant differences, between patients and healthy individuals, in response to this vaccination. 97 In a study including patients with primary Sjögren syndrome, similar proportions of seroconversion and seroprotection were achieved by patients and healthy individuals. 98 Biologic agents, B-cell depletion, treatment with DMARDs (except chloroquine-based anti malarial drugs and sulphasalazine) and lymphocytopenia negatively influenced humoral immune responses.…”

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

“…Of note, the pandemic H1N1 (2009) vaccination response rate in patients receiving immunosuppressive therapy for cGVHD was in the range of 42-33%, which is significantly lower than that in patients with systemic lupus erythematosus at a comparable intensity of immunosuppression, indicating an additional effect of the transplantation and cGvHD itself [23]. Issa et al [13] found lower rates of seroprotective titers to pandemic H1N1 (2009) vaccination in patients receiving mycophenolate mofetil.…”

“…In contrast, Mackay et al [22] found seroprotection in only 27% of patients with hematological malignancies compared to 50% in patients with solid tumors. Lu et al [23] recently reported on patients receiving systemic immunosuppression and described a seroprotection rate of 76.2% in patients with systemic lupus erythematosus after inactivated monovalent A/H1N1 (2009) vaccination. The results of different vaccination trials indicate that the risk/benefit ratio favors vaccination and that the furthest time point from chemotherapy is the best [24,25].…”